Since cells of this cancer lack the three common receptors, estrogen receptor (ER), progesterone receptor (PR), and hormone epidermal growth factor receptor 2 (HER-2), there are as yet no specific clinical drugs or targeting therapies for this kind of breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.